The regulation of blood glucose level in physical and emotional stress models: possible involvement of adrenergic and glucocorticoid systems.
This study was done to determine the effect of stress on blood glucose regulation in ICR mice. The stress was induced by the electrical foot shock-witness model. Blood glucose level was found to be increased in the electrical foot shock-induced physical stress group. Furthermore, the blood glucose levels were also elevated in the emotional stress group in both physical and emotional stress groups. The blood glucose level reached maximum 30 min after stress stimulation and returned to normal level 2 h after stress stimulation in both physical and emotional stress groups. Subsequently, we observed that intraperitoneal injection of phentolamine (an α1-adrenergic receptor antagonist), yohimbine (an α2-adrenergic receptor antagonist) or RU486 (a glucocorticoid receptor blocker) significantly inhibited blood glucose level induced by both physical and emotional stress. The results of our study suggest that physical and emotional stress increases blood glucose level via activation of adrenergic and glucocorticoid system.
Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon, Korea.
Yun-Beom
YB
Sim
Soo-Hyun
SH
Park
Yu-Jung
YJ
Kang
Seon-Mi
SM
Kim
Jin-Koo
JK
Lee
Jun-Sub
JS
Jung
Hong-Won
HW
Suh
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D058669:Adrenergic alpha-2 Receptor Antagonists / Q000627:therapeutic use; D000819:Animal Communication; D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D004558:Electric Stimulation / Q000009:adverse effects; D006943:Hyperglycemia / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D015735:Mifepristone / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010775:Photic Stimulation / Q000009:adverse effects; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors / Q000502:physiology*; D013312:Stress, Physiological / Q000187:drug effects; D013315:Stress, Psychological / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology*; D015016:Yohimbine / Q000627:therapeutic use
D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D001786:Blood Glucose; D011942:Receptors, Adrenergic, alpha; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D011965:Receptors, Glucocorticoid; D015016:Yohimbine; D015735:Mifepristone; D010646:Phentolamine